Women in whom oncogenic HPV types are not detected are at very low risk of cervical intraepithelial neoplasia grade 3 (CIN3) and cervical cancer for at least 5 years (see Chapter 2. The rationale for primary HPV screening). MSACThe Australian Medical Services Advisory Committee recommended that these women can continue 5-yearly screening (see Medical Services Advisory Committee recommendations for HPV testing).
|MSACThe Australian Medical Services Advisory Committee evidence-based recommendation|
REC6.1: Oncogenic HPV typesOncogenic HPV are HPV types considered capable of causing cancer. Types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 and 68 are included in tests suitable for cervical screening. Some tests also detect type 66. not detected at routine screening
- Katki HA, Kinney WK, Fetterman B, Lorey T, Poitras NE, Cheung L, et al. Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a population-based study in routine clinical practice. Lancet Oncol 2011 Jul;12(7):663-72 Abstract available at http://www.ncbi.nlm.nih.gov/pubmed/21684207.
- Dillner J, Rebolj M, Birembaut P, Petry KU, Szarewski A, Munk C, et al. Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study. BMJ 2008 Oct 13;337:a1754 Abstract available at http://www.ncbi.nlm.nih.gov/pubmed/18852164.
- Medical Services Advisory Committee. MSAC Outcomes. Application No. 1276 – Renewal of the National Cervical Screening Program. [homepage on the internet] Canberra: Australian Government Department of Health; 2014 [updated 2015 Apr]. Available from: http://www.msac.gov.au/internet/msac/publishing.nsf/Content/FD36D6990FFAA639CA25799200058940/$File/1276%20-%20Final%20MSAC%20PSD%20-%20NCSP%20Renewal.pdf.